Business
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP marketATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy-Induced Neuropathi
About this update from Dogwood Therapeutics, Inc.
[{"type":"image","alt":"Dogwood Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dogwood Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ymONq2rYrZZXJkVRmE8SRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f","width":300,"height":300}},"lazy":false},{"type":"text","content":"Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market","length":95,"tagName":"p"},{"type":"text","content":"ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy-Induced Neuropathic Pain), evaluating Halneuron® for the treatment of neuropathic pain associated with prior chemotherapy treatment (“CINP”).","length":528,"tagName":"p"},{"type":"text","content":"“Halneuron® is being developed to specifically inhibit the NaV 1.7 sodium channel, given the well-established role of this target in pain transmission,” said Greg Duncan, Dogwood’s Chairman and Chief Executive Officer. “We believe Halneuron’s® inherent specificity and potency may enable physicians to use very low doses of Halneuron® to both reduce pain and minimize the off-target effects that have limited prior NaV 1.7 development candidates.”","length":447,"tagName":"p"},{"type":"text","content":"Halneuron® is a first-in-class, NaV 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to chronic pain treatment with opioids. Patients treated with Halneuron® demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron® has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies and shows no signs of addiction potential.","length":477,"tagName":"p"},{"type":"text","content":"“Our goal is to recruit 100 patients with CINP by the fo...